NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT
申请人:AHN-GOOK PHARMACEUTICAL CO., LTD.
公开号:US20150210635A1
公开(公告)日:2015-07-30
The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11β-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11β-HSD1 (11β-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11β-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.
A one-pot aziridine opening reaction by glycosyl thiols generated in situ from the corresponding anomeric thio-acetates affords thio-glycosides with a pseudo-disaccharide structure and an N-linked tether. The scope of the one-pot aziridine opening reaction was explored on a series of mono- and disaccharides, creating a class of pseudo-glycosidic compounds with potential for further functionalization
Enhancing Substrate–Metal Catalyst Affinity via Hydrogen Bonding: Pd(II)-Catalyzed β-C(sp<sup>3</sup>)–H Bromination of Free Carboxylic Acids
作者:Liang Hu、Guangrong Meng、Xiangyang Chen、Joseph S. Yoon、Jing-Ran Shan、Nikita Chekshin、Daniel A. Strassfeld、Tao Sheng、Zhe Zhuang、Rodolphe Jazzar、Guy Bertrand、K. N. Houk、Jin-Quan Yu
DOI:10.1021/jacs.3c04223
日期:2023.8.2
While hydrogen bonding has been harnessed to bias siteselectivity in existing C(sp2)–H activation reactions, the potential for designing catalysts with hydrogen bond donors (HBDs) to enhance catalyst–substrate affinity and, thereby, facilitate otherwise unreactive C(sp3)–H activation remains to be demonstrated. Herein, we report the discovery of a ligand scaffold containing a remote amide motif that
The first syntheses of bioactive cryptophycins functionalized at unit ID were accomplished ina one-pot Staudinger reduction/cyclization step An a/ado precursor for the lower part of the backbone was introduced to minimize protective group chemistry and enable a very convenient synthesis of cryptophycin-52 and unit D eryptophycin analogues containing an ester or a free carboxylic acid for bioconjugations Both new cryptophycin derivatives show high biological activity in cytotoxicity assays
Facile access to pseudo-thio-1,2-dimannoside, a new glycomimetic DC-SIGN antagonist
The synthesis and conformational analysis of pseudo-thio-1,2-dimannoside are described. This molecule mimics mannobioside (Man alpha(1,2)Man) and is an analog of pseudo-1,2-dimannoside, with expected increased stability to enzymatic hydrolysis. A short and efficient synthesis was developed based on an epoxide ring-opening reaction by a mannosyl thiolate, generated in situ from the corresponding thioacetate. NMR-NOESY studies supported by MM3* calculations showed that the pseudo-thio-1,2-dimannoside shares the conformational behavior of the pseudo-1,2-dimannoside and is a structural mimic of the natural disaccharide. Its affinity for DC-SIGN was measured by SPR and found to be comparable to the corresponding O-linked analog, offering good opportunities for further developments. (C) 2017 Elsevier Ltd. All rights reserved.